

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-5. (Canceled)

6. (Currently Amended) A pharmaceutical composition comprising a peptide analogue comprising residues 87-99 of human myelin basic protein, wherein ~~at least~~ the lysine residue at position 91 is altered to another amino acid; and wherein the peptide analogue is not in the form of a noncovalent complex with a Major Histocompatibility (MHC) component; in combination with a physiologically acceptable carrier or diluent.

7. (Currently Amended) A method of treating multiple sclerosis, comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition comprising a peptide analogue comprising residues 87-99 of human myelin basic protein, wherein ~~at least~~ the lysine residue at position 91 is altered to another amino acid; and wherein the peptide analogue is not in the form of a noncovalent complex with a Major Histocompatibility (MHC) component, in combination with a physiologically acceptable carrier or diluent.

8. (Original) The method of claim 7 wherein the amino acid at position 91 is altered with an amino acid selected from the group consisting of D-lysine, alanine, glycine, glutamic acid, phenylalanine, arginine, asparagine, histidine, leucine and serine.

9. (Original) The method of claim 7 wherein the amino acid at position 91 is altered to a non-conservative amino acid.

10. (Original) The method of claim 7 wherein the amino acid at position 91 is altered to alanine.

11. (Original) The method of claim 7 wherein the analogue causes reduced expression of TNF- α from MBP-reactive T cells relative to the native sequence.